



Collegium to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference

July 6, 2016

CANTON, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Tuesday, July 12, 2016 at 8 a.m. Eastern Time. The conference will be held at Le Parker Meridian New York.

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx[®] technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

About Xtampza ER

Xtampza[®] ER is Collegium's first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

For Important Safety Information Visit, <http://www.xtampzaer.com/>

Contact:

Douglas Carlson
Vice President, Corporate Development
dcarlson@collegiumpharma.com



Collegium Pharmaceutical, Inc